应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
VTYX Ventyx Biosciences, Inc.
盘前交易 09-18 08:21:50 EDT
2.32
-0.02
-0.85%
盘前
2.38
+0.06
+2.59%
08:10 EDT
最高
2.44
最低
2.28
成交量
59.00万
今开
2.35
昨收
2.34
日振幅
6.84%
总市值
1.64亿
流通市值
1.15亿
总股本
7,067万
成交额
137.87万
换手率
1.19%
流通股本
4,968万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Ventyx Biosciences, Inc.盘中异动 股价大涨5.35%
市场透视 · 09-14
Ventyx Biosciences, Inc.盘中异动 股价大涨5.35%
Ventyx Biosciences, Inc.盘中异动 快速下跌5.04%报2.26美元
市场透视 · 08-27
Ventyx Biosciences, Inc.盘中异动 快速下跌5.04%报2.26美元
Ventyx Biosciences, Inc.盘中异动 快速拉升5.53%报2.08美元
市场透视 · 08-23
Ventyx Biosciences, Inc.盘中异动 快速拉升5.53%报2.08美元
Ventyx Biosciences, Inc.盘中异动 快速拉升5.05%报2.06美元
市场透视 · 08-22
Ventyx Biosciences, Inc.盘中异动 快速拉升5.05%报2.06美元
Ventyx Biosciences, Inc.盘中异动 急速拉升5.14%
自选股智能写手 · 08-20
Ventyx Biosciences, Inc.盘中异动 急速拉升5.14%
Ventyx Biosciences, Inc.2024财年第二财季实现净利润-31.95百万美元,同比增加40.00%
自选股智能写手 · 08-19
Ventyx Biosciences, Inc.2024财年第二财季实现净利润-31.95百万美元,同比增加40.00%
Ventyx Biosciences, Inc.盘中异动 大幅上涨5.24%
自选股智能写手 · 08-16
Ventyx Biosciences, Inc.盘中异动 大幅上涨5.24%
Ventyx 生物科学公司公布截至 6 月的季度业绩 - 收益摘要
Reuters · 08-13
Ventyx 生物科学公司公布截至 6 月的季度业绩 - 收益摘要
Ventyx Biosciences, Inc.盘中异动 股价大跌5.31%报1.96美元
自选股智能写手 · 08-12
Ventyx Biosciences, Inc.盘中异动 股价大跌5.31%报1.96美元
Ventyx Biosciences Inc 预计每股亏损 55 美分 - 财报前瞻
Reuters · 08-10
Ventyx Biosciences Inc 预计每股亏损 55 美分 - 财报前瞻
Ventyx Biosciences, Inc.盘中异动 股价大涨6.06%报2.10美元
自选股智能写手 · 08-09
Ventyx Biosciences, Inc.盘中异动 股价大涨6.06%报2.10美元
Ventyx Biosciences, Inc.盘中异动 下午盘大幅跳水5.10%报1.96美元
自选股智能写手 · 08-08
Ventyx Biosciences, Inc.盘中异动 下午盘大幅跳水5.10%报1.96美元
Ventyx Biosciences, Inc.盘中异动 大幅下挫5.77%报1.96美元
自选股智能写手 · 08-05
Ventyx Biosciences, Inc.盘中异动 大幅下挫5.77%报1.96美元
Ventyx Biosciences, Inc.盘中异动 早盘股价大跌5.13%
自选股智能写手 · 08-02
Ventyx Biosciences, Inc.盘中异动 早盘股价大跌5.13%
Ventyx Biosciences, Inc.盘中异动 股价大涨5.92%报2.42美元
自选股智能写手 · 07-30
Ventyx Biosciences, Inc.盘中异动 股价大涨5.92%报2.42美元
Ventyx Biosciences(VTYX.US)TYK2抑制剂II期克罗恩病临床失败
智通财经 · 07-30
Ventyx Biosciences(VTYX.US)TYK2抑制剂II期克罗恩病临床失败
【Ventyx Biosciences(VTYX.US)TYK2抑制剂II期克罗恩病临床失败】智通财经APP获悉,7月29日,Ventyx Biosciences(VTYX.
智通财经 · 07-30
【Ventyx Biosciences(VTYX.US)TYK2抑制剂II期克罗恩病临床失败】智通财经APP获悉,7月29日,Ventyx Biosciences(VTYX.
成分股Novocure、Guardant Health、Castle Biosciences、Anavex Life Sciences涨9.
华尔街见闻 · 07-30
成分股Novocure、Guardant Health、Castle Biosciences、Anavex Life Sciences涨9.
BUZZ--美国股票走势-Ventyx 生物科学公司、麦当劳、Pinterest
Reuters · 07-30
BUZZ--美国股票走势-Ventyx 生物科学公司、麦当劳、Pinterest
BUZZ-肠道疾病药物中期研究失败,Ventyx Biosciences业绩下滑
Reuters · 07-29
BUZZ-肠道疾病药物中期研究失败,Ventyx Biosciences业绩下滑
公司概况
公司名称:
Ventyx Biosciences, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Ventyx Biosciences, Inc.于2018年11月21日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司,专注于为数百万患有炎症性疾病和自身免疫性疾病的患者开发新疗法。该公司相信,他们有选择性地调节关键免疫靶点以创造差异化药物的能力将使他们有可能破坏成熟的价值数十亿美元的商业市场,并使他们成为免疫学市场的领导者。
发行价格:
--
{"stockData":{"symbol":"VTYX","market":"US","secType":"STK","nameCN":"Ventyx Biosciences, Inc.","latestPrice":2.32,"timestamp":1726603200000,"preClose":2.34,"halted":0,"volume":590027,"hourTrading":{"tag":"盘前","latestPrice":2.38,"preClose":2.32,"latestTime":"08:10 EDT","volume":1999,"amount":4757.62,"timestamp":1726661446852},"delay":0,"floatShares":49680589,"shares":70669131,"eps":-2.736933,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.02,"latestTime":"09-18 08:21:50 EDT","open":2.35,"high":2.44,"low":2.28,"amount":1378684.111437,"amplitude":0.068376,"askPrice":2.42,"askSize":826,"bidPrice":2.32,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.736933,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1726666200000},"adr":0,"listingDate":1634788800000,"adjPreClose":2.32,"preHourTrading":{"tag":"盘前","latestPrice":2.38,"preClose":2.32,"latestTime":"08:10 EDT","volume":1999,"amount":4757.62,"timestamp":1726661446852},"postHourTrading":{"tag":"盘后","latestPrice":2.42,"preClose":2.32,"latestTime":"16:48 EDT","volume":6681,"amount":15521.72,"timestamp":1726606136870},"volumeRatio":0.9698571910229958,"impliedVol":0.7386,"impliedVolPercentile":0.1793},"requestUrl":"/m/hq/s/VTYX/wiki","defaultTab":"wiki","newsList":[{"id":"2467750703","title":"Ventyx Biosciences, Inc.盘中异动 股价大涨5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2467750703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467750703?lang=zh_cn&edition=full","pubTime":"2024-09-14 00:04","pubTimestamp":1726243450,"startTime":"0","endTime":"0","summary":"北京时间2024年09月14日00时04分,Ventyx Biosciences, Inc.股票出现波动,股价快速拉升5.35%。Ventyx Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.05%。其相关个股中,Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Instil Bio, Inc.涨幅较大,Windtree Therapeutics, Inc.、Immuneering Corporation、Galmed Pharmaceuticals Ltd.较为活跃,换手率分别为829.17%、401.96%、107.32%,振幅较大的相关个股有Immuneering Corporation、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Instil Bio, Inc.,振幅分别为51.75%、48.21%、45.18%。Ventyx Biosciences, Inc.公司简介:Ventyx Biosciences Inc 是一家临床阶段的生物制药公司,专注于为数百万炎症性疾病和自身免疫性疾病患者发展新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240914000411a1da3754&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240914000411a1da3754&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2462197377","title":"Ventyx Biosciences, Inc.盘中异动 快速下跌5.04%报2.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2462197377","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462197377?lang=zh_cn&edition=full","pubTime":"2024-08-27 23:18","pubTimestamp":1724771921,"startTime":"0","endTime":"0","summary":"北京时间2024年08月27日23时18分,Ventyx Biosciences, Inc.股票出现波动,股价快速下跌5.04%。Ventyx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.30%。Ventyx Biosciences, Inc.公司简介:Ventyx Biosciences Inc 是一家临床阶段的生物制药公司,专注于为数百万炎症性疾病和自身免疫性疾病患者发展新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240827231841ab60247a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240827231841ab60247a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2461597706","title":"Ventyx Biosciences, Inc.盘中异动 快速拉升5.53%报2.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461597706","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461597706?lang=zh_cn&edition=full","pubTime":"2024-08-23 22:01","pubTimestamp":1724421671,"startTime":"0","endTime":"0","summary":"北京时间2024年08月23日22时01分,Ventyx Biosciences, Inc.股票出现异动,股价快速上涨5.53%。Ventyx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.44%。Ventyx Biosciences, Inc.公司简介:Ventyx Biosciences Inc 是一家临床阶段的生物制药公司,专注于为数百万炎症性疾病和自身免疫性疾病患者发展新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240823220111ab5f6a4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240823220111ab5f6a4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2461874706","title":"Ventyx Biosciences, Inc.盘中异动 快速拉升5.05%报2.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461874706","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461874706?lang=zh_cn&edition=full","pubTime":"2024-08-22 02:25","pubTimestamp":1724264711,"startTime":"0","endTime":"0","summary":"北京时间2024年08月22日02时25分,Ventyx Biosciences, Inc.股票出现波动,股价大幅拉升5.05%。Ventyx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.03%。Ventyx Biosciences, Inc.公司简介:Ventyx Biosciences Inc 是一家临床阶段的生物制药公司,专注于为数百万炎症性疾病和自身免疫性疾病患者发展新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082202251197199840&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082202251197199840&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2460006357","title":"Ventyx Biosciences, Inc.盘中异动 急速拉升5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460006357","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460006357?lang=zh_cn&edition=full","pubTime":"2024-08-20 02:33","pubTimestamp":1724092403,"startTime":"0","endTime":"0","summary":"北京时间2024年08月20日02时33分,Ventyx Biosciences, Inc.股票出现异动,股价急速拉升5.14%。Ventyx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.97%。Ventyx Biosciences, Inc.公司简介:Ventyx Biosciences Inc 是一家临床阶段的生物制药公司,专注于为数百万炎症性疾病和自身免疫性疾病患者发展新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082002332398e35684&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082002332398e35684&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2460043717","title":"Ventyx Biosciences, Inc.2024财年第二财季实现净利润-31.95百万美元,同比增加40.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460043717","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460043717?lang=zh_cn&edition=full","pubTime":"2024-08-19 00:00","pubTimestamp":1723996844,"startTime":"0","endTime":"0","summary":"8月19日,Ventyx Biosciences, Inc.公布财报,公告显示公司2024财年第二财季净利润为-31.95百万美元,同比增加40.00%;其中营业收入为0.00美元,每股基本收益为-0.45美元。从资产负债表来看,Ventyx Biosciences, Inc.总负债28.40百万美元,其中短期债务971000.00美元,资产负债比为0.11,流动比率为0.15。机构评级:截至2024年8月19日,当前有7家机构对Ventyx Biosciences, Inc.目标价做出预测,其中目标均价为11.57美元,其中最低目标价为2.00美元,最高目标价为21.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081900005395a383f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081900005395a383f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTYX"],"gpt_icon":0},{"id":"2459709614","title":"Ventyx Biosciences, Inc.盘中异动 大幅上涨5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459709614","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459709614?lang=zh_cn&edition=full","pubTime":"2024-08-16 00:27","pubTimestamp":1723739266,"startTime":"0","endTime":"0","summary":"北京时间2024年08月16日00时27分,Ventyx Biosciences, Inc.股票出现异动,股价快速拉升5.24%。Ventyx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为1.43%。Ventyx Biosciences, Inc.公司简介:Ventyx Biosciences Inc 是一家临床阶段的生物制药公司,专注于为数百万炎症性疾病和自身免疫性疾病患者发展新疗法。消息层面,截至00时27分,Ventyx Biosciences, Inc.股票正面舆情新闻比例100%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081600274697198da1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081600274697198da1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VTYX"],"gpt_icon":0},{"id":"2459952407","title":"Ventyx 生物科学公司公布截至 6 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2459952407","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459952407?lang=zh_cn&edition=full","pubTime":"2024-08-13 05:02","pubTimestamp":1723496537,"startTime":"0","endTime":"0","summary":" * Ventyx Biosciences Inc 报告,截至6月底的季度调整后每股亏损45美分,高于去年同期的每股-91美分。八位分析师对该季度的平均预期是每股亏损 58 美分。华尔街预期为每股-69美分至-50美分。* Ventyx Biosciences Inc 报告的季度每股收益为亏损 45 美分。* 该公司当季亏损 3195 万美元。* Ventyx Biosciences Inc 的股价本季度下跌了 10.4%,今年迄今为止下跌了 16.2%。* 生物技术和医学研究同行的平均一致建议也是 \"买入\"。华尔街对 Ventyx Biosciences Inc 的 12 个月目标价中位数为 10.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Ventyx 生物科学公司公布截至 6 月的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTYX"],"gpt_icon":0},{"id":"2458339986","title":"Ventyx Biosciences, Inc.盘中异动 股价大跌5.31%报1.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458339986","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458339986?lang=zh_cn&edition=full","pubTime":"2024-08-12 21:34","pubTimestamp":1723469667,"startTime":"0","endTime":"0","summary":"北京时间2024年08月12日21时34分,Ventyx Biosciences, Inc.股票出现异动,股价急速下挫5.31%。Ventyx Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.48%。其相关个股中,Revance Therapeutics, Inc.、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Oragenics Inc.涨幅较大,60 Degrees Pharmaceuticals, Inc.、Revance Therapeutics, Inc.、Oragenics Inc.较为活跃,换手率分别为47.06%、21.42%、16.49%,振幅较大的相关个股有Oragenics Inc.、Sangamo Therapeutics, Inc.、60 Degrees Pharmaceuticals, Inc.,振幅分别为30.36%、22.55%、21.44%。Ventyx Biosciences, Inc.公司简介:Ventyx Biosciences Inc 是一家临床阶段的生物制药公司,专注于为数百万炎症性疾病和自身免疫性疾病患者发展新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240812213428aefe6ae4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240812213428aefe6ae4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VTYX"],"gpt_icon":0},{"id":"2458919526","title":"Ventyx Biosciences Inc 预计每股亏损 55 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2458919526","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458919526?lang=zh_cn&edition=full","pubTime":"2024-08-10 08:05","pubTimestamp":1723248324,"startTime":"0","endTime":"0","summary":" * ) Ventyx Biosciences Inc 预计在11月4日公布截至0001年1月1日的业绩(,季度收入将没有变化。* * LSEG分析师对Ventyx Biosciences Inc的平均预期是每股亏损55美分。* 目前分析师对该公司股票的平均评级为 \"买入\",建议的细目为6个 \"强烈买入 \"或 \"买入\",3个 \"持有\",没有 \"卖出 \"或 \"强烈卖出\"。* 华尔街对 Ventyx Biosciences Inc 的 12 个月目标价中值为 10.00 美元,高于其上一次收盘价 2.07 美元。8月10日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Ventyx Biosciences Inc 预计每股亏损 55 美分 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTYX"],"gpt_icon":0},{"id":"2458599879","title":"Ventyx Biosciences, Inc.盘中异动 股价大涨6.06%报2.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458599879","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458599879?lang=zh_cn&edition=full","pubTime":"2024-08-09 21:31","pubTimestamp":1723210284,"startTime":"0","endTime":"0","summary":"北京时间2024年08月09日21时31分,Ventyx Biosciences, Inc.股票出现异动,股价快速拉升6.06%。Ventyx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.32%。其相关个股中,Pasithea Therapeutics Corp C/Wts 12/08/2026 、Third Harmonic Bio, Inc.、Adma Biologics Inc涨幅较大,Conduit Pharmaceuticals Inc.、Cns Pharmaceuticals, Inc.、Entero Therapeutics Inc.较为活跃,换手率分别为32.35%、5.26%、4.90%,振幅较大的相关个股有Brainstorm Cell Therapeutics Inc.、Enliven Therapeutics, Inc.、Relmada Therapeutics, Inc.,振幅分别为10.21%、9.58%、9.57%。Ventyx Biosciences, Inc.公司简介:Ventyx Biosciences Inc 是一家临床阶段的生物制药公司,专注于为数百万炎症性疾病和自身免疫性疾病患者发展新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809213124958bfd9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809213124958bfd9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2457082745","title":"Ventyx Biosciences, Inc.盘中异动 下午盘大幅跳水5.10%报1.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457082745","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457082745?lang=zh_cn&edition=full","pubTime":"2024-08-08 01:19","pubTimestamp":1723051183,"startTime":"0","endTime":"0","summary":"北京时间2024年08月08日01时19分,Ventyx Biosciences, Inc.股票出现波动,股价大幅下跌5.10%。Ventyx Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为2.38%。其相关个股中,G1 Therapeutics, Inc.、Tc Biopharm Plc C/Wts 10/02/2028 、Aditxt, Inc.涨幅较大,Aditxt, Inc.、Salarius Pharmaceuticals, Inc.、Scorpius Holdings, Inc.较为活跃,换手率分别为5009.48%、1781.15%、326.10%,振幅较大的相关个股有Aditxt, Inc.、Tc Biopharm Plc C/Wts 10/02/2028 、Salarius Pharmaceuticals, Inc.,振幅分别为101.30%、69.66%、55.91%。Ventyx Biosciences, Inc.公司简介:Ventyx Biosciences Inc 是一家临床阶段的生物制药公司,专注于为数百万炎症性疾病和自身免疫性疾病患者发展新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808011944941ff17e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808011944941ff17e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VTYX"],"gpt_icon":0},{"id":"2457720208","title":"Ventyx Biosciences, Inc.盘中异动 大幅下挫5.77%报1.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457720208","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457720208?lang=zh_cn&edition=full","pubTime":"2024-08-05 21:31","pubTimestamp":1722864697,"startTime":"0","endTime":"0","summary":"北京时间2024年08月05日21时31分,Ventyx Biosciences, Inc.股票出现波动,股价急速下跌5.77%。Ventyx Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为0.73%。其相关个股中,Zevra Therapeutics, Inc.、Cns Pharmaceuticals, Inc.、Protara Therapeutics, Inc.涨幅较大,Cns Pharmaceuticals, Inc.、Dermata Therapeutics, Inc.、Senti Biosciences, Inc.较为活跃,换手率分别为978.06%、33.14%、13.54%,振幅较大的相关个股有60 Degrees Pharmaceuticals, Inc.、Cue Biopharma, Inc.、Compass Therapeutics, Inc.,振幅分别为18.32%、12.33%、12.19%。Ventyx Biosciences, Inc.公司简介:Ventyx Biosciences Inc 是一家临床阶段的生物制药公司,专注于为数百万炎症性疾病和自身免疫性疾病患者发展新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080521313796823eb8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080521313796823eb8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2456353287","title":"Ventyx Biosciences, Inc.盘中异动 早盘股价大跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2456353287","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456353287?lang=zh_cn&edition=full","pubTime":"2024-08-02 22:01","pubTimestamp":1722607260,"startTime":"0","endTime":"0","summary":"北京时间2024年08月02日22时01分,Ventyx Biosciences, Inc.股票出现波动,股价大幅下挫5.13%。Ventyx Biosciences, Inc.股票所在的生物技术行业中,整体跌幅为1.08%。其相关个股中,Exicure, Inc.、Dermata Therapeutics, Inc.、Os Therapies Incorporated涨幅较大,Dermata Therapeutics, Inc.、Exicure, Inc.、Cns Pharmaceuticals, Inc.较为活跃,换手率分别为2313.39%、547.88%、47.39%,振幅较大的相关个股有Os Therapies Incorporated、Exicure, Inc.、Dermata Therapeutics, Inc.,振幅分别为54.19%、49.18%、38.71%。Ventyx Biosciences, Inc.公司简介:Ventyx Biosciences Inc 是一家临床阶段的生物制药公司,专注于为数百万炎症性疾病和自身免疫性疾病患者发展新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802220100af95a797&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802220100af95a797&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VTYX"],"gpt_icon":0},{"id":"2455674955","title":"Ventyx Biosciences, Inc.盘中异动 股价大涨5.92%报2.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2455674955","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455674955?lang=zh_cn&edition=full","pubTime":"2024-07-30 22:19","pubTimestamp":1722349146,"startTime":"0","endTime":"0","summary":"北京时间2024年07月30日22时19分,Ventyx Biosciences, Inc.股票出现异动,股价急速拉升5.92%。Ventyx Biosciences, Inc.股票所在的生物技术行业中,整体涨幅为0.99%。其相关个股中,Imunon, Inc.、Processa Pharmaceuticals, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026涨幅较大,Processa Pharmaceuticals, Inc.、Imunon, Inc.、Cns Pharmaceuticals, Inc.较为活跃,换手率分别为1470.81%、937.64%、859.78%,振幅较大的相关个股有Imunon, Inc.、Processa Pharmaceuticals, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026,振幅分别为74.79%、52.35%、49.65%。Ventyx Biosciences, Inc.公司简介:Ventyx Biosciences Inc 是一家临床阶段的生物制药公司,专注于为数百万炎症性疾病和自身免疫性疾病患者发展新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240730221906aefc3504&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240730221906aefc3504&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2455629944","title":"Ventyx Biosciences(VTYX.US)TYK2抑制剂II期克罗恩病临床失败","url":"https://stock-news.laohu8.com/highlight/detail?id=2455629944","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455629944?lang=zh_cn&edition=full","pubTime":"2024-07-30 10:36","pubTimestamp":1722306984,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,7月29日,Ventyx Biosciences宣布,其变构TYK2抑制剂VTX958在中度至重度活动性克罗恩病患者进行的II期研究未达主要终点。这并不是VTX958首次折戟。2023年11月,在中重度斑块状银屑病II期研究中,虽然225mg、300mg VTX958剂量组均达到了主要终点以及所有次要终点,但因疗效不足,也就是这些有效性数据并不足以支持其在竞争激烈的银屑病、银屑病关节炎赛道的进一步开发,最终Ventyx决定终止VTX958治疗银屑病和银屑病关节炎适应症的II期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1157227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VTYX","BK4007"],"gpt_icon":0},{"id":"2455362918","title":"【Ventyx Biosciences(VTYX.US)TYK2抑制剂II期克罗恩病临床失败】智通财经APP获悉,7月29日,Ventyx Biosciences(VTYX.","url":"https://stock-news.laohu8.com/highlight/detail?id=2455362918","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455362918?lang=zh_cn&edition=full","pubTime":"2024-07-30 10:36","pubTimestamp":1722306984,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03347","BK1141","VTYX","BK1583","BK1576","BK4007"],"gpt_icon":0},{"id":"2455617899","title":"成分股Novocure、Guardant Health、Castle Biosciences、Anavex Life Sciences涨9.","url":"https://stock-news.laohu8.com/highlight/detail?id=2455617899","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455617899?lang=zh_cn&edition=full","pubTime":"2024-07-30 05:01","pubTimestamp":1722286891,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/us-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/us-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["VTYX","BK4139","TRML","BK4007"],"gpt_icon":0},{"id":"2455660055","title":"BUZZ--美国股票走势-Ventyx 生物科学公司、麦当劳、Pinterest","url":"https://stock-news.laohu8.com/highlight/detail?id=2455660055","media":"Reuters","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455660055?lang=zh_cn&edition=full","pubTime":"2024-07-30 00:03","pubTimestamp":1722269018,"startTime":"0","endTime":"0","summary":" * 个股走势的 Eikon 搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 7月29日 - 纳斯达克指数和标普500指数周一上涨,受超级大盘股提振,投资者正在等待大型科技公司的业绩、美联储的政策决定以及本周关键的劳动力数据。美东时间11:42,道琼斯工业平均指数 下跌0.25%,报40,488.42点。标普500指数 下跌0.07%,报5455.14点;纳斯达克综合指数 下跌0.08%,报17343.934点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QID","IART","PINS","AKAM","GH","LU0823411888.USD","L","DXD","BUZZ","TQQQ",".DJI","CNA","LU1023059063.AUD","IE00BJT1NW94.SGD","ON","MCD","UDOW","DJX","LU0082616367.USD","QLD","PR",".IXIC","BMRC","DDM","ARE","VTYX","NQmain",".SPX","DOG","RVTY","ESGR","BK4223","LU0348723411.USD","PSQ","MNQmain","CPTN","SQQQ","NDAQ","LU1585245621.USD","LU0053666078.USD","SDOW","ABT","INSP","SG9999015952.SGD"],"gpt_icon":1},{"id":"2455666036","title":"BUZZ-肠道疾病药物中期研究失败,Ventyx Biosciences业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2455666036","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455666036?lang=zh_cn&edition=full","pubTime":"2024-07-29 22:20","pubTimestamp":1722262825,"startTime":"0","endTime":"0","summary":" 7月29日 - ** Ventyx Biosciences 股价下跌约26%,至2.19美元 ** 该公司称其克罗恩病实验药物在一项中期研究中未能达到主要目标** 克罗恩病是一种炎症性肠病,会导致消化道组织肿胀** 与安慰剂相比,药物VTX958在治疗12周后未能减轻疾病的严重程度** Stifel分析师亚历克斯-汤普森在一份报告中写道:\"鉴于该药物之前在银屑病研究中的失败 ,试验结果 \"不足为奇\"。** VTYX公司表示,它不打算利用内部资源对VTX958进行更多的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","BK4007","VTYX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.ventyxbio.com","stockEarnings":[{"period":"1week","weight":0.0691},{"period":"1month","weight":0.2541},{"period":"3month","weight":-0.1564},{"period":"6month","weight":-0.6844},{"period":"1year","weight":-0.9386},{"period":"ytd","weight":-0.0607}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":0.0158},{"period":"3month","weight":0.0266},{"period":"6month","weight":0.0783},{"period":"1year","weight":0.2692},{"period":"ytd","weight":0.1846}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ventyx Biosciences, Inc.于2018年11月21日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司,专注于为数百万患有炎症性疾病和自身免疫性疾病的患者开发新疗法。该公司相信,他们有选择性地调节关键免疫靶点以创造差异化药物的能力将使他们有可能破坏成熟的价值数十亿美元的商业市场,并使他们成为免疫学市场的领导者。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.01538},{"month":2,"riseRate":0.666667,"avgChangeRate":0.701385},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.095926},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.042289},{"month":5,"riseRate":0.666667,"avgChangeRate":0.133308},{"month":6,"riseRate":0,"avgChangeRate":-0.288909},{"month":7,"riseRate":1,"avgChangeRate":0.12313},{"month":8,"riseRate":0.333333,"avgChangeRate":0.07183},{"month":9,"riseRate":1,"avgChangeRate":0.262783},{"month":10,"riseRate":0,"avgChangeRate":-0.328778},{"month":11,"riseRate":0,"avgChangeRate":-0.329199},{"month":12,"riseRate":1,"avgChangeRate":0.095095}],"exchange":"NASDAQ","name":"Ventyx Biosciences, Inc.","nameEN":"Ventyx Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ventyx Biosciences, Inc.(VTYX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ventyx Biosciences, Inc.(VTYX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ventyx Biosciences, Inc.,VTYX,Ventyx Biosciences, Inc.股票,Ventyx Biosciences, Inc.股票老虎,Ventyx Biosciences, Inc.股票老虎国际,Ventyx Biosciences, Inc.行情,Ventyx Biosciences, Inc.股票行情,Ventyx Biosciences, Inc.股价,Ventyx Biosciences, Inc.股市,Ventyx Biosciences, Inc.股票价格,Ventyx Biosciences, Inc.股票交易,Ventyx Biosciences, Inc.股票购买,Ventyx Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ventyx Biosciences, Inc.(VTYX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ventyx Biosciences, Inc.(VTYX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}